← Leaderboards
Eric Hollander
Icahn School Of Medicine At Mount Sinai
$2,001,963
Attributed
$2,001,963
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $517.4K · FY2008–20$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
FDA$1,855,253 · 2
NIH$146,710 · 5
By mechanism
R01$1,855,253 · 2
T32$121,028 · 1
M01$25,682 · 4
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Latha Valluripalli Soorya$2,786,769
- Jin Fan$2,314,808
- Virginia R Litle$161,739
- Yasmin L Hurd$58,238,356
- Hirofumi Morishita$17,178,343
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesInstitutionSourceGrantResearch PersonnelFundingUnited States National Institutes Of HealthComputer Retrieval Of Information On Scientific Projects DatabaseAutistic DisorderAdultWeekBasePlacebosBehaviorSeriesPsychopharmacologyAffectiveRandomizedDouble-Blind MethodDiagnosisChildEligibility DeterminationClinical ResearchDesign
Grant awards (11)
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome [IND 121109 acknowledged 8/27/14]$499,311
R01 · FY2020 · FD · contact PI
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome [IND 121109 acknowledged 8/27/14]$435,569
R01 · FY2018 · FD · contact PI
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome [IND 121109 acknowledged 8/27/14]$57,079
R01 · FY2018 · FD · contact PI
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome [IND 121109 acknowledged 8/27/14]$492,648
R01 · FY2017 · FD · contact PI
FLUOXETINE IN PEDIATRIC BODY DYSMORPHIC DISORDER$337,730
R01 · FY2008 · FD · contact PI
Training in Psychopharmacology and Outcomes Research$121,028
T32 · FY2008 · MH · contact PI
FLUOXETINE IN PEDIATRIC BODY DYSMORPHIC DISORDER$32,916
R01 · FY2008 · FD · contact PI
GREATER NEW YORK AUTISM CENTER OF EXCELLENCE - CLINICAL CORE$12,555
M01 · FY2008 · RR · contact PI
INTRANASAL OXYTOCIN CHALLENGE IN BORDERLINE PERSONALITY$10,273
M01 · FY2008 · RR · contact PI
EARLY PHARMACOLOGIC INTERVENTION IN AUTISM: FLUOXETINE IN PRESCHOOL CHILDREN$1,712
M01 · FY2008 · RR · contact PI
DIVALPROEX SODIUM ER IN ADULT AUTISM$1,142
M01 · FY2008 · RR · contact PI